Gov. Josh Shapiro’s administration plans to save money by cutting poor patients’ access to expensive weight-loss drugs like ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for the drugs, which often retail at more than $1,000 ...

For years, Patricia Williamson struggled with weight loss ... versions due to high prices. But the FDA ended the shortage designation on the compounded drugs in 2025, and the medicines ...

Appetite-suppressing drugs could wipe out millions of fast-food trips. What it means for your choices and your money.

Through nifty marketing and an insurance-circumventing subscription model that delivers medicine directly to your front door, ...

As costs continue to rise, employers are looking to the levers they have available to get their arms around this challenge, ...

Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be ...

AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is ...

Hims & Hers has been expanding its presence in the weight management market, with its existing Novo partnership representing ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...